ERBB2 and breast carcinoma: It is known that PI3K/Akt activation is essential for HER2-mediated apoptosis suppression22, 23; activation of the PI3K/Akt pathway by different mechanisms has been described both in HER2+ breast cancer patients with trastuzumab resistance24 and in BT474r cells12.